First-Line Treatment of Metastatic Pancreatic Cancer

  • Mohammed Tokh University of Massachusetts. Worcester, MA, USA
  • Venu Bathini University of Massachusetts. Worcester, MA, USA
  • Muhammad Wasif Saif Columbia University College of Physicians and Surgeons. New York, NY, USA
Keywords: 2-(4-ethoxyphenyl)-4-methyl 1-(4-sulfamoylphenyl)-1H-pyrrole, gemcitabine, IPI-926, MUC-1 monoclonal antibody, Pancreatic Neoplasms, Radioimmunotherapy, temsirolimus


Metastatic pancreatic cancer is an aggressive malignancy that is difficult to treat. Gemcitabine monotherapy has been used first line and many contemporary treatment approaches have focused on gemcitabine plus experimental agents. The 2012 ASCO Gastrointestinal Cancers Symposium Abstract #213 is a study of gemcitabine with IPI-926, a novel hedgehog pathway inhibitor. Abstract #227 is a study of gemcitabine with 90Y-hPAM4 radioimmunotherapy with yttrium labeled anti-mucin humanized antibody. Abstract #296 is a study of gemcitabine with temsirolimus, an mTOR inhibitor. Gemcitabine and erlotinib has shown slight advantages to gemcitabine alone. Abstract #253 takes this one step further and evaluates gemcitabine and erlotinib with apricoxib, a COX-2 inhibitor. FOLFIRINOX has shown superiority to gemcitabine; however, doing so at the cost of significantly greater toxicity. Abstract #199, is a study which examines the cost effectiveness of first line FOLFIRINOX approaches. Another cost effective study is portrayed in Abstract #372, a study evaluating the survival of unresectable pancreatic cancer patients treated with gemcitabine and the disease course is followed clinically without radiographic follow-up.


Download data is not yet available.


Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.

Ries LA, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1973-1996. National Cancer Institute, Bethesda, MD 2000.

Crown J, Casper ES, Botet J, et al. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 1991; 9:1682.

DeCaprio JA, Mayer RJ, Gonin R, Arbuck SG. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol 1991; 9:2128.

Van Rijswijk RE, Jeziorski K, Wagener DJ, et al. Weekly high-dose 5-fluorouracil and folinic acid in metastatic pancreatic carcinoma: a phase II study of the EORTC GastroIntestinal Tract Cancer Cooperative Group. Eur J Cancer 2004; 40:2077.

Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403.

Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000; 60:2926.

Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960.

Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010; 28:3605.

Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817.

Ma YT, Hussain SA, Johnson PJ, Palmer DH. Gemcitabine chemotherapy until symptomatic disease progression in advanced pancreatic cancer: A retrospective analysis. J Clin Oncol 30, 2012 (suppl 4; abstr 372).

Attard CL, Brown S, Alloul K, Moore MJ. Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer. J Clin Oncol 30, 2012 (suppl 4; abstr 199).

Donald Anthony Richards, Joe Stephenson, Brian M. Wolpin, Carlos Becerra, John Turner Hamm, Wells A. Messersmith, Shannon Devens, Jill Cushing, Tess Schmalbach, Charles S. Fuchs. A phase Ib trial of IPI-926, a hedgehog pathway inhibitor, plus gemcitabine in patients with metastatic pancreatic cancer. J Clin Oncol 30, 2012 (suppl 4; abstr 213).

Ocean AJ, Guarino MJ, Pennington KL, Springett GM, Gulec SA, Bekaii-Saab TS, Montero AJ, Mitchell EP, Kauh JS, Sung MW, Gold DV, Horne H, Wegener WA, Goldenberg DM. Activity of fractionated radioimmunotherapy (RAIT) with 90Y clivatuzumab tetraxetan (90Y-hPAM4) plus gemcitabine (Gem) in advanced pancreatic cancer (APC): Final results from a two-part study. J Clin Oncol 30, 2012 (suppl 4; abstr 227).

Modiano M, Keogh GP, Manges R, Stella PJ, Milne G, Looper E, Zaknoen SL. Apricot-P: A randomized placebo controlled phase II study of COX-2 inhbitor apricoxib or placebo in combination with gemcitabine and erlotinib in advanced or metastatic adenocarcinoma of the pancreas. J Clin Oncol 30, 2012 (suppl 4; abstr 253).

Faris JE, Blaszkowsky LS, Abrams TA, Enzinger PC, Hezel AF, Wolpin BM, Ryan DP, Kwak EL. A phase I study of temsirolimus in combination with gemcitabine in previously untreated metastatic pancreatic cancer. J Clin Oncol 30, 2012 (suppl 4; abstr 296).

Aaron Lazare Medical Research Building, University of Massachusetts Medical School, Worcester, MA, USA
How to Cite
TokhM., BathiniV., & SaifM. (2012). First-Line Treatment of Metastatic Pancreatic Cancer. JOP. Journal of the Pancreas, 13(2), 159-162.
Highlights from the “2012 ASCO Gastrointestinal Cancers Symposium”. San Francisco, CA, USA. January 19-21, 2012